APA (7th ed.) Citation

C, L., D, Y., A, P., Y, H., R, Z., W, Z., . . . E, J. (2025). Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation. Hematology (Amsterdam, Netherlands), 30(1), 2509353. https://doi.org/10.1080/16078454.2025.2509353

Chicago Style (17th ed.) Citation

C, Liang, et al. "Gilteritinib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/refractory Acute Myeloid Leukemia with FLT3-internal Tandem Duplication Mutation." Hematology (Amsterdam, Netherlands) 30, no. 1 (2025): 2509353. https://doi.org/10.1080/16078454.2025.2509353.

MLA (9th ed.) Citation

C, Liang, et al. "Gilteritinib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/refractory Acute Myeloid Leukemia with FLT3-internal Tandem Duplication Mutation." Hematology (Amsterdam, Netherlands), vol. 30, no. 1, 2025, p. 2509353, https://doi.org/10.1080/16078454.2025.2509353.